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Macro-level efficiency of health expenditure: estimates for 15 major economies 1 
Abstract 2 
The coronavirus disease 2019 (COVID-19) pandemic highlights the importance of strong and 3 
resilient health systems. Yet how much a society should spend on healthcare is difficult to 4 
determine because additional health expenditures imply lower expenditures on other types of 5 
consumption. Furthermore, the welfare-maximizing (“efficient”) aggregate amount and 6 
composition of health expenditures depend on efficiency concepts at three levels that often get 7 
blurred in the debate. While the understanding of efficiency is good at the micro- and meso- 8 
levels—that is, relating to minimal spending for a given bundle of treatments and to the optimal 9 
mix of different treatments, respectively—this understanding rarely links to the efficiency of 10 
aggregate health expenditure at the macroeconomic level. While micro- and meso-efficiency are 11 
necessary for macro-efficiency, they are not sufficient. We propose a novel framework of a macro- 12 
efficiency score to assess welfare-maximizing aggregate health expenditure. This allows us to 13 
assess the extent to which selected major economies underspend or overspend on health relative 14 
to their gross domestic products per capita. We find that all economies under consideration 15 
underspend on healthcare with the exception of the United States. Underspending is particularly 16 
severe in China, India, and the Russian Federation. Our study emphasizes that the major and urgent 17 
issue in many countries is underspending on health at the macroeconomic level, rather than 18 
containing costs at the microeconomic level. 19 
Key words: health expenditure; efficiency; value of statistical life; welfare; macroeconomics; 20 










To tackle health emergencies, such as the coronavirus disease 2019 (COVID-19) pandemic, and 23 
to cope with the health-related challenges of the unprecedented population aging that the world 24 
currently faces (Bloom et al., 2020; Bloom et al., 2018; Bloom et al., 2015; Chen & Bloom, 2019; 25 
Chen et al., 2018; Chen et al., 2019b), nations need strong and resilient health systems. Countries’ 26 
health expenditures increased strongly in recent decades, not just in absolute terms but also as 27 
shares of their gross domestic products (GDPs) (Papanicolas et al., 2018). This increase is expected 28 
to continue over the coming years and to reach more than US$24 trillion by 2040 (Dieleman et al., 29 
2017). Yet the important question of whether such high spending levels are optimal remains largely 30 
unanswered. While one analysis suggests that the spending level for the United States may be too 31 
low (Hall & Jones, 2007), this result remains up for debate (D. Cutler, 2021) and systematic and 32 
rigorous investigations of other countries are scarce. 33 
Facing growing health expenditures, many researchers question the efficiency of the healthcare 34 
sector. Previous studies suggest that inefficiencies exist in the production, organization, and 35 
administration of healthcare; in the allocation of health expenditure across services and sub-groups 36 
of the population; and in the adoption of new technologies (Baicker et al., 2012; Berwick & 37 
Hackbarth, 2012; Chandra & Skinner, 2012; Chandra & Staiger, 2020; D. M. Cutler, 2018; D. M. 38 
Cutler & Ly, 2011; A. M. Garber & Skinner, 2008). However, these studies mainly focus on micro- 39 
level (or production) efficiency, i.e. the production of a given volume and type of healthcare using 40 
minimal inputs, or on meso-level (or allocative) efficiency in the sense of a welfare-maximizing 41 
mix of healthcare services for a given aggregate healthcare budget (Jacobs et al., 2006; World 42 









expenditure in the sense of a welfare-maximizing mix of aggregate health expenditure and 44 
spending on other goods and services (consumption in particular). 45 
Exploring macro-level efficiency of health expenditure is crucial for policymaking. Decisions 46 
based solely on the micro-level and meso-level efficiency of health expenditure may lead to the 47 
wide implementation of cost-containment strategies such as regulating drug prices, lowering costs 48 
in public hospitals, and setting spending caps for healthcare services (Busse & Blümel, 2014; 49 
Busse et al., 2017; Busse et al., 2013; A. Garber et al., 2007; Li, 2011; G. G. Liu et al., 2017; X. 50 
Liu et al., 2019; Mossialos & Le Grand, 2019; Stabile et al., 2013; Stadhouders et al., 2019; Yip 51 
et al., 2019) that could be counterproductive from an aggregate perspective. This is because, at the 52 
aggregate level, the share of health expenditure in GDP may be inefficiently low and cost- 53 
containment strategies may exacerbate this problem, inter alia, by impeding quality and innovation 54 
in healthcare. To understand why, it is important to recognize that two fundamentally different 55 
factors drive high and growing health expenditure shares. These factors are (i) overspending due 56 
to inefficiency in the production and allocation of healthcare and (ii) a high demand for efficiently 57 
provided healthcare that grows even further in times of population aging. Separating efficient from 58 
inefficient spending increases is challenging both conceptually and practically.  59 
In this article we focus on the macroeconomic efficiency of health expenditure, i.e., whether 60 
countries underspend or overspend on healthcare relative to all other types of consumption. We 61 
provide a novel and simple way to test for macro-efficiency and determine the extent to which the 62 
following important large economies—Argentina, Australia, Brazil, Canada, China, France, 63 
Germany, India, Italy, Japan, the Russian Federation, South Africa, Spain, the United Kingdom, 64 










Data sources 67 
To perform the test for 15 large economies, we rely on World Development Indicators (2021) data 68 
on life expectancy, consumption expenditures as a share of GDP, health expenditures as a share of 69 
GDP, and GDP itself (World Bank, 2021). In the main analysis, we use data for 2015 and, in 70 
further analysis, we also use 2010 data to show how the macro-efficiency score changed over time. 71 
As a specification for instantaneous utility, we apply a standard isoelastic utility function. As the 72 
inverse of the elasticity of intertemporal substitution, i.e., a measure of how willing households 73 
are to sacrifice consumption today in exchange for consumption tomorrow, we use the value 1.01, 74 
which is well in line with empirical evidence (Chetty, 2006). In addition, we consider that 75 
individuals discount their future utility at a rate of 2.5% (Kuhn & Prettner, 2016). The main text 76 
provides details of our estimation of the elasticity of longevity with respect to health expenditure 77 
(henceforth “longevity elasticity”), while the Appendix provides a detailed description of the 78 
parameter values and data sources used in the simulations. 79 
Model structure 80 
Based on previous research (Hall & Jones, 2007), we derive from a simple model a macro- 81 
efficiency score that indicates whether an economy underspends or overspends on healthcare (see 82 
the Appendix for a full derivation). We assume individuals maximize their discounted lifetime 83 
utility 𝑢(𝑐) ∙ 𝐷𝐿𝐸(ℎ), as defined by the utility 𝑢(𝑐) from annual consumption 𝑐 multiplied by the 84 
individual’s discounted life expectancy at birth 𝐷𝐿𝐸(ℎ), which can be increased by annual health 85 
expenditure ℎ. Note that 𝐷𝐿𝐸(ℎ) is a measure (for a precise formulation, see the Appendix) that 86 









which individuals discount the future (i.e., the extent to which they prefer present day 88 
consumption).  89 
Individuals allocate their income to consumption, which raises their utility within each life year, 90 
and health investments, which increase life expectancy and allow the spread of consumption utility 91 
over additional life years, according to the budget constraint 𝑦 = 𝑐 + ℎ. We show in the Appendix 92 
that this yields an optimal spending rule, according to which the ratio of consumption expenditures 93 
to health expenditures equals the ratio of the elasticity of discounted life expectancy with respect 94 
to health expenditure (henceforth “discounted longevity elasticity”), 
𝐷𝐿𝐸′(ℎ)∙ℎ
𝐷𝐿𝐸(ℎ)
, and the elasticity of 95 
utility with respect to consumption, 
𝑢′(𝑐)∙𝑐
𝑢(𝑐)








 .  97 
The elasticities are defined as the percentage change in discounted longevity and utility for a 1% 98 
increase in health and consumption expenditures, respectively. Thus, they measure the 99 
effectiveness of health expenditure versus consumption in raising life-cycle utility.  100 
The optimal spending rule yields the following insights: (i) A richer country would, all else equal, 101 
spend more on healthcare relative to consumption. This follows from the fact that a lower elasticity 102 
of consumption utility typically characterizes rich countries, reflecting the decreasing effects of 103 
additional consumption on utility that follows from the hierarchy of individual needs. For a given 104 
discounted longevity elasticity, a rich country is thus willing to devote a greater share of income 105 
to healthcare. (ii) It can be shown (see Appendix) that the discounted longevity elasticity decreases 106 









of life expectancy and with more patient populations tend to value more an increase in longevity. 108 
(iii) Medical progress that raises the discounted longevity elasticity triggers a reallocation of 109 
available income from consumption to healthcare. (iv) Countries that for some reason are less 110 
effective in producing health, as measured by a lower discounted longevity elasticity, should, all 111 
else equal, spend less on healthcare. While many exogenous factors—such as demographic, social, 112 
cultural, and environmental determinants of health—may explain why countries differ in the 113 
productivity of their health expenditure, an intricate link exists between production efficiency and 114 
macroeconomic efficiency.  115 
Suppose two countries, A and B, share the same level of per capita GDP, but country B runs an 116 
inefficient health system and therefore exhibits a lower longevity elasticity. In this case, according 117 
to the optimal spending rule, country B should devote fewer resources to healthcare. While 118 
redirecting resources away from relatively inefficient use can be viewed as a “locally” optimal 119 
response, it would be misguided in global terms. The appropriate strategy would be to reorganize 120 
the health system toward improved efficiency and maintain (or, depending on the starting point, 121 
increase) overall health expenditure. Hence, whether “cost containment” reflects warranted 122 
efficiency gains or whether it reflects unwarranted spending cuts must be considered very 123 
carefully. 124 
In reality, the optimal spending rule may not be met because (i) lacking expert knowledge, 125 
individuals typically delegate most of their healthcare choices to physicians who, following their 126 
own objectives, may spend non-optimally (Arrow, 1963); (ii) where individuals determine 127 
spending levels, lack of information about treatment effectiveness may lead to suboptimal 128 
spending decisions; and (iii) the government and insurance firms determine spending levels, they 129 









evidence exists that government spending in the United States reflects special interests rather than 131 
the median voter’s preferences (Gilens & Page, 2014; Page et al., 2013). 132 
To assess the extent of underspending or overspending, we transform the optimal spending rule 133 
into a macro-efficiency score (Appendix, equation (2)). Underspending on healthcare prevails if 134 
the macro-efficiency score is less than 1, and the reverse holds true if the score exceeds 1. By 135 
setting the macro-efficiency score equal to 1, we can recalculate optimal health expenditures and, 136 
thus, the percentage gap between actual and optimal expenditures.  137 
Output estimates 138 
We calculate the macro-efficiency score for the following countries—Argentina, Australia, Brazil, 139 
Canada, China, France, Germany, India, Italy, Japan, the Russian Federation, South Africa, Spain, 140 
the United Kingdom, and the United States—to assess how much these countries underspend or 141 
overspend relative to their GDP per capita.  142 
Recalling that the utility elasticity with respect to consumption tends to fall with increasing 143 
consumption and, by implication, with increasing GDP per capita, determining the longevity 144 
elasticity is the only aspect that remains undone. Unfortunately, we lack country-specific data on 145 
this elasticity. To obtain an “average” measure, we use the data from the World Development 146 
Indicators (World Bank, 2021) to regress the log of life expectancy on the log of health 147 
expenditures, controlling for the log of per capita income, the share of people aged 65 and older, 148 
and the squared terms of the log of per capita income and the share of people above the age of 65. 149 
The inclusion of squared terms accounts for nonlinearities in the relationship. For countries with a 150 
GDP per capita higher than the global median, we obtain an estimate for the longevity elasticity 151 








by 0.051%. We then use this longevity elasticity to calculate the macro-efficiency score. We also 153 
derive the optimal health expenditure for each country. To provide changes across time, we further 154 
compute the macro-efficiency score for the year 2010 using the longevity elasticity of 0.061 155 
estimated for the year 2010. The Appendix provides further detail on parameter choices and data 156 
sources. 157 
Plausibility check based on the value of a statistical life  158 
One advantage of our approach is that it allows for computing an implied value of a statistical life 159 
(VSL) across countries that we can compare to the estimated value in a country, derived from the 160 
literature (Viscusi & Masterman, 2017). Doing so represents an independent plausibility check of 161 
our results on the extent of underspending or overspending on healthcare. See Appendix for 162 
further details on the VSL calculations. 163 
Sensitivity analysis 164 
Furthermore, we conduct a sensitivity analysis using the longevity elasticity of 0.04, as found in a 165 
meta-analysis of different estimates (Gallet & Doucouliagos, 2017). The Appendix provides 166 
further details on the mathematical formulation, parameter choices, and data sources. 167 
Results 168 
Macro-efficiency score and the assessment of underspending or overspending on health 169 
Table 1 presents the macro-efficiency scores that indicate whether a country underspends or 170 
overspends on healthcare. In 2015, Canada and Japan spent around 10% of their respective GDPs 171 









China, India, and the Russian Federation spent only around 4% to 5% of their GDPs on health. 173 
Judging from the macro-efficiency scores, all countries under consideration underinvest in 174 
healthcare except the United States. While the United States underspent in 2010, it overspent in 175 
2015, indicating that the current health expenditure share in GDP for the United States is likely to 176 
be near the optimal point. On the other side of the range, underinvestment is particularly 177 
pronounced in China, India, and the Russian Federation. 178 












(% of GDP) 
Argentina 0.49 9.45 0.54 8.79 
Australia 0.43 8.43 0.57 9.31 
Brazil 0.42 7.95 0.57 8.87 
Canada 0.55 10.68 0.65 10.51 
China 0.25 4.21 0.33 4.89 
France 0.59 11.24 0.73 11.46 
Germany 0.57 11.10 0.68 11.09 
India 0.18 3.27 0.24 3.60 
Italy 0.46 8.92 0.56 8.99 
Japan 0.48 9.16 0.70 10.89 
Russian Federation 0.23 4.97 0.30 5.30 
South Africa 0.34 7.42 0.48 8.20 
Spain 0.47 9.12 0.57 9.11 
UK 0.51 9.99 0.59 9.69 
US 0.85 16.35 1.05 16.84 
Note: The longevity elasticity is 0.061 and 0.051 for 2010 and 2015, respectively, and is based on our 180 
estimates using World Bank data. A macro-efficiency score in excess of 1 indicates overspending, while a 181 
score below 1 indicates underspending on healthcare. Health expenditure (% of GDP) is based on World 182 
Bank data. 183 
 184 









Figure 1 shows the gap between current and optimal health expenditure in GDP for each country 186 
in 2015. The countries are ranked by the gap between current and optimal health expenditure in 187 
GDP, which is largest in India (67.4%), followed by the Russian Federation (65.9%), China 188 
(63.8%), and South Africa (47.9%). In contrast, the United States overspent by 4.3%. 189 
Figure 1. Current and optimal health expenditure shares (% of GDP) 190 
191 
Note: The countries are sorted based on the percentage gap between the current versus optimal health 192 
expenditure share in GDP. The current health expenditure (% of GDP) is based on World Bank data from 193 
2015. The optimal health expenditure (% of GDP) is estimated from our framework using the longevity 194 
elasticity of 0.051. 195 
 196 
















Optimal Health Expenditure (% of GDP)









Plausibility check based on the value of a statistical life  197 
Table 2 shows our calculated VSL, which is a measure of how much individuals would be willing 198 
to pay for an instantaneous reduction in mortality (Hall & Jones, 2007; Murphy & Topel, 2006) 199 
and compares it with the micro-econometric estimates of Viscusi and Masterman (2017). Although 200 
the VSLs are derived by very different methods, they are of the same order of magnitude, 201 
underscoring the validity of our computations.  202 











Argentina 3.99 2.14 4.20 2.14 
Australia 7.27 10.34 7.96 10.34 
Brazil 2.21 1.70 2.41 1.70 
Canada 7.36 8.18 7.99 8.18 
China 0.66 1.36 1.11 1.36 
France 6.65 6.98 6.71 6.98 
Germany 7.40 7.90 7.78 7.90 
India 0.47 0.28 0.68 0.28 
Italy 7.48 5.65 7.04 5.65 
Japan 6.17 6.68 6.40 6.68 
Russian Federation 3.09 1.97 3.44 1.97 
South Africa 1.62 1.05 1.75 1.05 
Spain 6.13 4.91 6.21 4.91 
UK 7.77 7.47 8.39 7.47 
US 10.85 9.63 11.68 9.63 
Note: The longevity elasticity is 0.061 and 0.051 for 2010 and 2015, respectively, and is based on our 204 
estimates using World Bank data. The VSL (model) is calculated within our framework, while the VSL 205 
(estimated) is from Viscusi & Masterman (2017). 206 
 207 









We then conducted a sensitivity analysis using the lower longevity elasticity estimate of 0.04, 209 
taken from a recent meta-analysis (Gallet & Doucouliagos, 2017). The results remain robust, with 210 
India, the Russian Federation, and China having the lowest and the United States having the 211 
highest macro-efficiency scores. All countries except for the United States underspend on health. 212 
Table 3. Macro-efficiency score and health expenditure (% of GDP) in 2010 and 2015 using 213 












(% of GDP) 
Argentina 0.74 9.45 0.69 8.79 
Australia 0.66 8.43 0.73 9.31 
Brazil 0.64 7.95 0.73 8.87 
Canada 0.85 10.68 0.83 10.51 
China 0.38 4.21 0.42 4.89 
France 0.91 11.24 0.93 11.46 
Germany 0.87 11.10 0.88 11.09 
India 0.28 3.27 0.30 3.60 
Italy 0.70 8.92 0.71 8.99 
Japan 0.74 9.16 0.90 10.89 
Russian Federation 0.36 4.97 0.39 5.30 
South Africa 0.53 7.42 0.61 8.20 
Spain 0.73 9.12 0.73 9.11 
UK 0.78 9.99 0.75 9.69 
US 1.31 16.35 1.35 16.84 
Note: The longevity elasticity of 0.04 is estimated within a meta-regression consisting of 65 studies 215 
completed over the 1969–2014 period (Gallet & Doucouliagos, 2017). A macro-efficiency score in excess 216 
of 1 indicates overspending, while a score below 1 indicates underspending on healthcare. Health 217 











Underspending on healthcare 221 
This study, for the first time, estimates the macro-level efficiency of health expenditure for 15 222 
countries. We find that from a macroeconomic perspective, almost all countries included in our 223 
analysis would benefit from increasing their health expenditure. Despite their relatively high health 224 
expenditure shares, countries such as Argentina, Australia, Canada, Italy, Japan, and the United 225 
Kingdom would benefit from further expansion, as the high GDP levels in these countries translate 226 
into large VSLs. Underinvestment is particularly pronounced in China, India, and the Russian 227 
Federation due to the low share of health expenditures in GDP, which might be due to these 228 
countries following other priorities in spending, such as on infrastructure in the case of China 229 
(Chen et al., 2020).  230 
In general, the optimal shares of health expenditure in GDP are similar across countries, ranging 231 
between 14% in China and India to 16% in the United States. Although the lower GDP and 232 
associated VSL in China and India imply a lower optimal share of health expenditures in GDP, 233 
our macro-efficiency score indicates that the current spending shares are so low that these two 234 
countries would particularly benefit from spending increases. The situation is somewhat different 235 
for the Russian Federation and for South Africa, with both countries exhibiting optimal shares of 236 
health expenditures in GDP that are comparable to or even exceed those of countries with higher 237 
GDPs. Here the reason lies in the low levels of life expectancy, which tend to support a higher 238 
optimal share of health expenditures in GDP. Generally, given the longevity elasticity, the optimal 239 
health expenditure share in GDP is explained by both GDP (particularly low in China and India; 240 









low in Russia, South Africa, and India; particularly high in Japan) pointing at a lower spending 242 
share.    243 
Overall, the United States is the only country exhibiting overspending, particularly in 2015. The 244 
explanation for this is rooted in the relatively high share of health expenditure in GDP. To 245 
decidedly answer the question raised by Garber and Skinner (2008), “Is American healthcare 246 
uniquely inefficient?” we would, however, require more precise estimates of the longevity 247 
elasticity for the United States.  248 
Our study emphasizes that the major and urgent issue in many countries is underinvestment in 249 
health at the macroeconomic level, rather than containing costs at the microeconomic level. 250 
Countries should further expand their healthcare sectors by increasing investment and promoting 251 
innovation of high-quality and effective care that can increase longevity. While such an expansion 252 
should be executed in a way that is micro-efficient, our analysis shows that an exclusive focus on 253 
expenditure containment is inappropriate. Health expenditure should not be viewed simply as a 254 
burden; rather, it is a reflection of countries’ modernization and respect for their citizens, whose 255 
wellbeing depends decisively on living long and healthy lives.   256 
Valuing health at the macroeconomic level 257 
Our result that most countries included in our analysis underspend on healthcare is based on a 258 
relatively narrow macro-efficiency criterion relating to income and the effectiveness of healthcare 259 
in raising life expectancy. We would expect an even stronger case for investments in health and 260 









First, investments in health and healthcare can drive economic growth by improving population 262 
health. Healthier populations tend to have higher labor force participation rates, greater 263 
productivity, and longer working lifespans (Bloom & Canning, 2000; Bloom et al., 2019a; Bloom 264 
et al., 2020; Bloom et al., 2019b; Bloom et al., 2018; Bloom et al., 2019c; Chen & Bloom, 2019; 265 
Chen et al., 2018; Chen et al., 2019a, b; Well, 2007). With more of the population in employment 266 
and a higher production potential for each worker, a country with a healthier population can 267 
achieve higher per capita output. Longer life expectancy also incentivizes savings, education, and 268 
investment in research and development (R&D), which in turn contribute to economic growth 269 
(Ben-Porath, 1967; Bloom & Canning, 2000; Bloom et al., 2003; Cervellati & Sunde, 2005, 2013; 270 
Gehringer & Prettner, 2019; Prettner & Trimborn, 2017). These dynamic effects are, at best, 271 
incompletely reflected in the individual’s willingness to pay for healthcare and, thus, tend to imply 272 
that our macro-efficiency score is prone to underestimate the spending level required to attain 273 
macroeconomic efficiency in an economic growth context. 274 
Second, medical and healthcare services can also drive economic growth through technological 275 
innovation. Studies show that, as the size and value of the healthcare market increases, the extent 276 
of R&D activity on pharmaceuticals and advanced medical technology and their diffusion expands 277 
(Acemoglu & Linn, 2004; Clemens, 2013; Finkelstein, 2004, 2007; Frankovic & Kuhn, 2018; 278 
Frankovic et al., 2020). Large welfare gains can also be achieved even if many of the ensuing 279 
innovations are not cost-effective (Böhm et al., 2021; Chandra & Skinner, 2012; Fonseca et al., 280 
2020; Frankovic & Kuhn, 2018; Frankovic et al., 2020), which follows as a corollary to our finding 281 
that income growth should increasingly translate into health expenditure. Notably, this case is 282 
weakened to the extent that medical spending is subject to decreasing returns, leading to “flat-of- 283 









function upward, affording an increase in medical productivity throughout. Jones (2016) shows 285 
that under plausible assumptions about preferences, this is true even if medical R&D crowds out 286 
innovations aimed at conventional productivity growth. 287 
Third, investments in health and healthcare can also improve the quality and resilience of health 288 
systems, which can ensure social stability, especially in an emergency. A modern health system 289 
with a certain excess capacity in terms of equipment, beds, and staff can be viewed as a form of 290 
insurance against large-sized medical incidents, such as accidents involving mass casualties, 291 
natural or manmade disasters, and epidemic outbreaks of infectious diseases (Attema et al., 2010; 292 
Lakdawalla et al., 2017; Megiddo et al., 2019; Philipson & Zanjani, 2014; Zweifel et al., 2009). In 293 
today’s interconnected world, emerging infectious diseases with pandemic potential can cost 294 
millions of lives, cause economic upheaval, and disrupt travel and trade (Acemoglu et al., 2020; 295 
Eichenbaum et al., 2020; Glover et al., 2020; International Monetary Fund; International Monetary 296 
Fund; Krueger et al., 2020; U.S. Department of Health & Human Services, 2010). Developing 297 
modern health systems, advanced medical and healthcare technology, and sufficient capacity in 298 
terms of facilities, equipment, and trained staff are crucial to ensure not only health system 299 
stability, but social and economic stability as well. 300 
Strengths 301 
Against a large body of evidence on the productive efficiency of healthcare in various settings, 302 
this study is the first to provide an intuitive yet rigorous test for the macroeconomic efficiency of 303 
health expenditure. One strength is that we derive the macro-efficiency score from economic 304 
theory. A second strength is that the macro-efficiency score can be calculated based on relatively 305 









detailed data. Our approach allows for a straightforward assessment and ranking of the extent to 307 
which countries underspend or overspend on healthcare.  308 
Limitations 309 
Our analysis has several caveats. First and most important, our test only allows us to assess the 310 
deviation from a macro-efficient spending level that is conditional on an average production 311 
efficiency, as measured by the estimated longevity elasticity. Thus, while our conservative use of 312 
a lower estimate of the longevity elasticity than the one we estimate provides a robust assessment 313 
of the direction of macro-inefficiency for the countries under consideration, we cannot disentangle 314 
macro-inefficiency from micro-inefficiency (i.e., production inefficiency) at the country level. 315 
This implies that the measured macro-inefficiency (i.e., the deviation from 1) may to some extent 316 
be upward or downward biased.  317 
Second, our results are preconditioned on our use of life expectancy at birth as the outcome 318 
criterion. While this is consistent with the underlying framework in Hall and Jones (2007), it fails 319 
to incorporate explicitly quality-of-life dimensions of healthcare. That said, life expectancy is a 320 
plausible (long-run) proxy for health in itself (Vaupel, 2010), while, in economic terms, quality of 321 
life is a close complement to length of life in generating utility (Hall & Jones, 2007; Murphy & 322 
Topel, 2006). Assuming that countries choose a mix of healthcare that balances length of life and 323 
quality of life, one can then interpret life expectancy as a sufficient statistic for quality-related 324 
aspects of health as well (Chandra & Skinner, 2012). On these grounds, we argue for the robustness 325 
of our results when it comes to assessing the macro-efficiency of healthcare spending.  326 
Third, our test is based on the assumptions that (i) the social benefits of health expenditure equal 327 









while (ii) the opportunity cost of health expenditure is appropriately measured by the marginal 329 
utility of foregone consumption. Both (i) and (ii) require qualification, as (i) external benefits are 330 
likely to be associated with private health improvements, and (ii) the marginal utility of foregone 331 
consumption appropriately measures the opportunity cost of spending only when assuming that 332 
other investments chosen by the individual follow a similar optimality rule as that outlined in the 333 
optimal spending rule (Appendix, equation (1)). In particular, this is important in the context of 334 
spending on education. Extensive evidence exists on the complementarity of health and education 335 
as components of human capital, implying that underinvestment in one domain is associated with 336 
underinvestment in the other domain as well (Bleakley, 2007, 2010; Cervellati & Sunde, 2013, 337 
2015; Field et al., 2009; Hansen & Strulik, 2017; Jayachandran & Lleras-Muney, 2009; Lleras- 338 
Muney, 2005; Lucas, 2010; Miguel & Kremer, 2004). This suggests that our findings are on the 339 
conservative side. We provide further analysis and discussion in the Appendix. 340 
Fourth, we cannot easily extend our analysis to low-income countries. When running the 341 
regression for the countries below the median world income, the longevity elasticity is 342 
insignificant, mainly because mortality is determined by many aspects that are not closely related 343 
to health expenditures in these countries, such as hunger and a lack of clean drinking water. As 344 
such, we only include middle- and high-income countries in this study. 345 
We conclude by noting that all of these caveats predominantly relate to measurement issues, which 346 
the use of more elaborate indicators and/or additional data can address. They do not, however, 347 










While the understanding of efficiency in health spending is robust at the micro- and meso-levels,  350 
the efficiency of health expenditure at the macroeconomic level is less studied and understood. We 351 
developed a score to assess the macro-efficiency of health expenditure and found that Argentina, 352 
Australia, Brazil, Canada, China, France, Germany, India, Italy, Japan, the Russian Federation, 353 
South Africa, Spain, and the United Kingdom all underspend on healthcare and would benefit from 354 
devoting more resources to their healthcare sectors. The United States is the only country 355 
exhibiting overspending. Our study emphasizes that the major and urgent issue in many countries 356 
is underinvestment in health at the macroeconomic level, rather than containing costs at the 357 
microeconomic level. Health, healthcare, and medical science are essential to a citizenry’s welfare 358 
and are important for social stability. Health expenditure should not be viewed simply as a burden; 359 
rather, it is a reflection of countries’ modernization and respect for their citizens, whose wellbeing 360 
depends decisively on living long and healthy lives. Looking forward, a high-quality, responsive, 361 
and resilient health system and an efficient and innovative mechanism to promote R&D in public 362 
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